CORRECTING and REPLACING: MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
2023年1月10日 - 06:03AM
ビジネスワイヤ（英語）
Regulatory News:
This replaces the announcement made at 6pm CET on 9th January
2023 to include the financial tables.
MaaT Pharma (EURONEXT:
MAAT – the “Company”), a French clinical-stage biotech and a
pioneer in the development of Microbiome Ecosystem TherapiesTM
(MET) dedicated to improving survival outcomes for patients with
cancer, today announces its half-year report on the liquidity
contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity contract entered between MaaT Pharma and
Kepler Cheuvreux, the following resources appeared on the liquidity
account on December 31st, 2022:
- Number of executions on buy side on
semester: 390
- Number of executions on sell side on
semester: 330
- Traded volume on buy side on semester:
14,188 shares for €131,237.39
- Traded volume on sell side on semester:
9,342 shares for €86,141.84
As a reminder:
- the following resources appeared on the last half year
statement on 30 June 2022 on the liquidity account:
- Number of executions on buy side on
semester: 244
- Number of executions on sell side on
semester: 134
- Traded volume on buy side on semester:
12,600 shares for €153,377.30
- Traded volume on sell side on semester:
4,939 shares for €61,676.96
- the following resources appeared on the liquidity account when
the activity started:
The implementation of this report is carried out in accordance
with AMF Decision N°2021-01 of June 22nd, 2021, renewing the
implementation of liquidity contracts for shares as an accepted
market practice.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has already
achieved proof of concept in a Phase II clinical trial in acute
GvHD. Our powerful discovery and analysis platform, gutPrint®,
supports the development and expansion of our pipeline by
determining novel disease targets, evaluating drug candidates, and
identifying biomarkers for microbiome-related conditions.
The company’s Microbiome Ecosystem Therapies are produced
through a standardized cGMP manufacturing and quality control
process to safely deliver the full diversity of the microbiome, in
liquid and oral formulations. MaaT Pharma benefits from the
commitment of world-leading scientists and established
relationships with regulators to support the integration of the use
of microbiome therapies in clinical practice.
MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
Buy Side Sell Side Number
ofexecutions Number ofshare Traded
volumein EUR Number ofexecutions
Number ofshare Traded volumein EUR
Total
390
14,188
131,237.39
330
9.342
86,141.84
01/07/2022
7
400
4,340.00
1
1
11.30
04/07/2022
-
-
-
1
1
10.95
05/07/2022
2
200
2,150.00
2
10
109.50
06/07/2022
13
1.2
12,360.00
1
1
10.80
07/07/2022
7
304
3,100.80
-
-
-
08/07/2022
6
398
3,999.90
1
1
10.35
11/07/2022
-
-
-
2
100
1,010.00
12/07/2022
3
61
616.10
2
77
785.40
13/07/2022
1
1
10.15
4
125
1,285.00
14/07/2022
3
141
1,414.23
1
1
10.20
15/07/2022
1
1
10.15
3
12
122.40
18/07/2022
2
29
294.35
1
50
510.00
19/07/2022
1
1
10.20
4
122
1,252.94
20/07/2022
1
100
1,020.00
2
18
185.40
21/07/2022
1
1
10.20
1
1
10.20
22/07/2022
2
13
131.95
1
1
10.20
25/07/2022
6
459
4,599.18
1
2
20.20
26/07/2022
1
1
10.05
3
99
999.90
27/07/2022
1
1
10.05
1
1
10.05
28/07/2022
2
16
161.60
3
101
1,030.20
29/07/2022
1
85
858.50
-
-
-
01/08/2022
6
400
4,000.00
3
18
181.80
02/08/2022
2
130
1,297.40
4
182
1,847.30
03/08/2022
1
1
10.15
1
1
10.15
04/08/2022
2
15
150.15
1
1
10.10
05/08/2022
2
2
20.16
1
1
10.15
08/08/2022
-
-
-
3
28
285.60
09/08/2022
3
85
850.00
1
1
10.20
10/08/2022
1
1
10.05
4
272
2,755.36
11/08/2022
1
100
1,000.00
7
301
3,070.20
12/08/2022
1
100
1,010.00
3
149
1,530.23
15/08/2022
-
-
-
4
51
520.20
16/08/2022
1
100
1,010.00
3
41
418.20
17/08/2022
1
1
10.15
6
259
2,667.70
18/08/2022
2
105
1,071.00
4
300
3,120.00
19/08/2022
1
1
10.45
2
29
303.05
22/08/2022
1
5
51.00
1
22
228.80
23/08/2022
3
26
265.20
1
1
10.25
24/08/2022
4
166
1,683.24
1
1
10.25
25/08/2022
11
800
7,800.00
4
21
208.11
26/08/2022
1
100
980.00
2
180
1,792.80
29/08/2022
3
156
1,497.60
2
70
693.00
30/08/2022
2
60
588.00
-
-
-
31/08/2022
4
106
1,026.08
1
1
9.80
01/09/2022
2
185
1,748.25
1
1
9.70
02/09/2022
1
1
9.36
1
1
9.36
05/09/2022
-
-
-
3
121
1,173.70
06/09/2022
-
-
-
2
14
137.20
07/09/2022
-
-
-
2
12
118.80
08/09/2022
3
5
48.70
1
1
9.88
09/09/2022
2
77
746.90
1
1
9.72
12/09/2022
2
62
595.20
2
143
1,392.82
13/09/2022
11
472
4,422.64
9
333
3,213.45
14/09/2022
7
373
3,450.25
1
1
9.60
15/09/2022
2
16
150.40
2
51
484.50
16/09/2022
1
1
9.50
1
1
9.50
19/09/2022
9
795
7,329.90
-
-
-
20/09/2022
4
240
2,119.20
-
-
-
21/09/2022
8
591
4,793.01
4
360
3,034.80
22/09/2022
1
1
8.48
1
1
8.48
23/09/2022
-
-
-
2
255
2,193.00
26/09/2022
2
63
526.68
2
30
261.00
27/09/2022
7
272
2,208.64
8
347
2,991.14
28/09/2022
3
31
266.91
1
1
8.78
29/09/2022
12
556
4,509.16
1
13
110.50
30/09/2022
-
-
-
2
100
820.00
03/10/2022
2
61
494.10
5
61
506.30
04/10/2022
5
228
1,780.68
5
107
847.44
05/10/2022
4
183
1,374.33
3
81
634.23
06/10/2022
6
148
1,107.04
2
78
616.20
07/10/2022
-
-
-
6
312
2,505.36
10/10/2022
-
-
-
6
85
705.50
11/10/2022
3
81
648.00
2
4
32.36
12/10/2022
1
1
8.00
3
26
208.52
13/10/2022
2
6
48.12
1
1
8.10
14/10/2022
2
26
208.00
8
323
2,719.66
17/10/2022
-
-
-
7
362
3,196.46
18/10/2022
3
110
984.50
9
563
5,264.05
19/10/2022
1
1
8.92
6
92
839.04
20/10/2022
1
20
184.00
2
60
564.00
21/10/2022
1
1
9.22
1
1
9.22
24/10/2022
5
172
1,565.20
-
-
-
25/10/2022
5
18
162.90
1
1
9.16
26/10/2022
1
1
9.02
2
11
99.99
27/10/2022
2
17
154.70
3
88
809.60
28/10/2022
6
81
732.24
1
1
9.18
31/10/2022
4
195
1,727.70
-
-
-
01/11/2022
4
28
241.92
5
256
2,298.88
03/11/2022
1
1
8.98
1
1
8.98
04/11/2022
2
35
312.90
-
-
-
07/11/2022
5
189
1,663.20
2
64
569.60
08/11/2022
1
1
8.80
1
16
142.40
09/11/2022
1
1
8.90
-
-
-
10/11/2022
2
21
186.90
4
136
1,228.08
11/11/2022
1
1
9.18
5
35
325.15
14/11/2022
1
1
9.22
1
1
9.22
15/11/2022
2
31
285.20
1
1
9.22
16/11/2022
7
178
1,575.30
5
88
785.84
17/11/2022
11
113
977.45
4
32
281.60
18/11/2022
4
42
368.76
-
-
-
21/11/2022
1
1
8.72
3
31
274.66
22/11/2022
1
20
176.00
1
1
9.00
23/11/2022
1
1
8.80
1
1
8.80
24/11/2022
6
78
675.48
-
-
-
25/11/2022
-
-
-
5
100
882.00
28/11/2022
2
44
387.20
-
-
-
29/11/2022
5
94
812.16
1
1
8.80
30/11/2022
1
1
8.62
8
110
980.10
01/12/2022
-
-
-
3
50
453.00
02/12/2022
6
132
1,191.96
7
305
2,836.50
05/12/2022
1
1
8.92
3
101
909.00
06/12/2022
2
88
778.80
-
-
-
07/12/2022
1
1
8.80
2
13
115.57
08/12/2022
1
1
8.90
1
1
8.90
09/12/2022
2
100
880.00
-
-
-
12/12/2022
-
-
-
4
100
900.00
13/12/2022
5
190
1,725.20
5
252
2,308.32
14/12/2022
6
260
2,360.80
7
251
2,324.26
15/12/2022
5
150
1,320.00
1
10
89.00
16/12/2022
5
93
814.68
4
31
275.90
19/12/2022
4
38
329.08
1
10
87.00
20/12/2022
8
96
814.08
4
42
367.50
21/12/2022
7
111
945.72
3
61
528.87
22/12/2022
1
20
168.00
2
17
145.18
23/12/2022
1
1
8.52
1
1
8.52
27/12/2022
3
60
513.00
2
43
374.10
28/12/2022
8
161
1,323.42
4
84
695.52
29/12/2022
6
230
1,860.70
7
147
1,208.34
30/12/2022
14
611
4,845.23
7
251
2,005.49
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230109005788/en/
MaaT Pharma Hervé AFFAGARD Co-Founder and CEO Siân
CROUZET, COO/ CFO +33 4 28 29 14 00 invest@maat-pharma.com
MaaT Pharma Pauline RICHAUD Senior PR & Corporate
Communications Manager +33 6 07 55 25 36
prichaud@maat-pharma.com
Trophic Communications Corporate Communications Jacob
VERGHESE or Gretchen SCHWEITZER +49 89 23 88 77 31
maat@trophic.eu
Maat Pharma (EU:MAAT)
過去 株価チャート
から 5 2023 まで 6 2023
Maat Pharma (EU:MAAT)
過去 株価チャート
から 6 2022 まで 6 2023
